VIP and metabolic dysfunction-associated steatotic liver disease: In conclusion, our findings highlight the potential for targeting VIP signaling and ILC3 as a novel therapeutic strategy to ameliorate hepatic steatosis and highlight the need to further understand how neuroimmune modulation can affect metabolic disorders, including MASLD.